| Year |
Citation |
Score |
| 2020 |
Golay J, Taylor RP. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies (Basel, Switzerland). 9. PMID 33126570 DOI: 10.3390/antib9040058 |
0.373 |
|
| 2020 |
Taylor RP, Lindorfer MA. How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca. Antibodies (Basel, Switzerland). 9. PMID 32899722 DOI: 10.3390/Antib9030045 |
0.355 |
|
| 2020 |
Taylor RP, Lindorfer MA, Atkinson JP. Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes. Alzheimer's & Dementia (New York, N. Y.). 6: e12067. PMID 32885023 DOI: 10.1002/Trc2.12067 |
0.333 |
|
| 2020 |
Zhang Y, Kremsdorf R, Sperati CJ, Henriksen KJ, Mori M, Goodfellow RX, Pitcher GR, Benson C, Borsa NG, Taylor RP, Nester CM, Smith RJ. Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome. Kidney International. PMID 32540405 DOI: 10.1016/J.Kint.2020.05.028 |
0.302 |
|
| 2020 |
Oostindie SC, van der Horst HJ, Kil LP, Strumane K, Overdijk MB, van den Brink EN, van den Brakel JHN, Rademaker HJ, van Kessel B, van den Noort J, Chamuleau MED, Mutis T, Lindorfer MA, Taylor RP, Schuurman J, et al. DuoHexaBody-CD37, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer Journal. 10: 30. PMID 32341336 DOI: 10.1038/S41408-020-0292-7 |
0.433 |
|
| 2020 |
Kil LP, Oostindie SC, Strumane K, Horst HJvd, Kessel Bv, Overdijk MB, Lingnau A, Brandhorst M, Brakel Jvd, Lindorfer MA, Taylor RP, Chamuleau ME, Mutis T, Sasser AK, Schuurman J, et al. Abstract 4544: Multifaceted mechanism of action of DuoHexaBody-CD37 involves both complement- and Fc gamma receptor-mediated cytotoxicity in pre-clinical B-cell lymphoma models Immunology. 80: 4544-4544. DOI: 10.1158/1538-7445.Am2020-4544 |
0.398 |
|
| 2019 |
Xavier S, Sahu RK, Bontha SV, Mass V, Taylor RP, Megyesi J, Thielens NM, Portilla D. Complement C1r serine protease contributes to kidney fibrosis. American Journal of Physiology. Renal Physiology. PMID 31509012 DOI: 10.1152/Ajprenal.00357.2019 |
0.317 |
|
| 2019 |
Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, et al. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. Plos Biology. 17: e3000323. PMID 31216278 DOI: 10.1371/Journal.Pbio.3000323 |
0.385 |
|
| 2019 |
Taylor RP. Null donors favor prepared immunologists. Blood. 133: 1389-1390. PMID 30923104 DOI: 10.1182/Blood-2019-01-898775 |
0.33 |
|
| 2019 |
Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, ... ... Taylor RP, et al. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. Haematologica. PMID 30792198 DOI: 10.3324/Haematol.2018.207266 |
0.453 |
|
| 2019 |
Desai S, Drinkwater D, Mo CC, Farooqui MZ, Soto S, Valdez J, Gaglione EM, Tian X, Nierman P, Lotter J, Marti G, Nichols C, Taneja A, Herman SEM, Maric I, ... ... Taylor RP, et al. Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study Blood. 134: 5474-5474. DOI: 10.1182/Blood-2019-126698 |
0.369 |
|
| 2018 |
Vercellotti GM, Dalmasso AP, Schaid TR, Nguyen J, Chen C, Ericson ME, Abdulla F, Killeen T, Lindorfer MA, Taylor RP, Belcher JD. Critical role of C5a in sickle cell disease. American Journal of Hematology. PMID 30569594 DOI: 10.1002/Ajh.25384 |
0.363 |
|
| 2018 |
Taylor RP, Lindorfer MA. Mechanisms of Complement-Mediated Damage in Hematological Disorders. Seminars in Hematology. 55: 118-123. PMID 30032747 DOI: 10.1053/J.Seminhematol.2018.02.003 |
0.339 |
|
| 2018 |
Oostindie SC, Van Der Horst HJ, Overdijk MB, Strumane K, Verploegen S, Lindorfer MA, Cook EM, Chamuleau ME, Mutis T, Schuurman J, Sasser AK, Taylor RP, Parren PWHI, Beurskens FJ, Breij ECW. Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models Blood. 132: 4170-4170. DOI: 10.1182/Blood-2018-99-114723 |
0.426 |
|
| 2018 |
Taylor R, Lindorfer M, Oostindie S, Cook E, Zent C, Burack R, Beurskens F, Schuurman J, Breij E, Parren P. Hexamerization-enhanced CD37 and CD20 antibodies synergize in CDC to kill patient-derived CLL cells with unprecedented potency Molecular Immunology. 102: 218. DOI: 10.1016/J.Molimm.2018.06.222 |
0.347 |
|
| 2018 |
Gulati S, Beurskens FJ, de Kreuk B, Roza M, Zheng B, Taylor RP, Botto M, Schuurman J, Rice PA, Ram S. Potentiation of efficacy of a candidate immunotherapeutic antibody to Neisseria gonorrhoeae by enhancing IgG Fc hexamer formation Molecular Immunology. 102: 157. DOI: 10.1016/J.Molimm.2018.06.083 |
0.401 |
|
| 2017 |
Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, ... ... Taylor RP, et al. Corrigendum: IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions. Nature Immunology. 18: 1173. PMID 28926542 DOI: 10.1038/Ni1017-1173C |
0.351 |
|
| 2017 |
Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, ... ... Taylor RP, et al. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions. Nature Immunology. PMID 28604720 DOI: 10.1038/Ni.3770 |
0.456 |
|
| 2017 |
Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Paul Morgan B. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. Clinical Immunology (Orlando, Fla.). PMID 28578024 DOI: 10.1016/J.Clim.2017.05.016 |
0.37 |
|
| 2017 |
Taylor RP. Neutrophils: positive or negative? Blood. 129: 2596-2597. PMID 28495923 DOI: 10.1182/Blood-2017-03-774695 |
0.401 |
|
| 2017 |
Xavier S, Sahu RK, Landes SG, Yu J, Taylor RP, Ayyadevara S, Megyesi J, Stallcup WB, Duffield JS, Reis ES, Lambris JD, Portilla D. Pericyte and immune cells contribute to complement activation in tubulointerstitial fibrosis. American Journal of Physiology. Renal Physiology. ajprenal.00604.2016. PMID 28052876 DOI: 10.1152/Ajprenal.00604.2016 |
0.34 |
|
| 2016 |
Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP. Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology (Orlando, Fla.). PMID 27546448 DOI: 10.1016/J.Clim.2016.08.017 |
0.334 |
|
| 2016 |
Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. Journal of Immunology (Baltimore, Md. : 1950). PMID 27474078 DOI: 10.1016/J.Imbio.2016.06.018 |
0.456 |
|
| 2016 |
Taylor RP, Lindorfer MA. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Seminars in Immunology. PMID 27009480 DOI: 10.1016/J.Smim.2016.03.003 |
0.395 |
|
| 2016 |
Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, de Jong RN, Beurskens FJ, Schuurman J, Parren PW, Taylor RP. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. Molecular Immunology. 70: 13-23. PMID 26690706 DOI: 10.1016/J.Molimm.2015.12.007 |
0.391 |
|
| 2016 |
Schaid TR, Nguyen J, Chen C, Abdulla F, Killeen T, Nguyen H, Edmund J, Lindorfer MA, Taylor RP, Dalmasso AP, Belcher JD, Vercellotti GM. Complement Activation in a Murine Model of Sickle Cell Disease: Inhibition of Vaso-Occlusion By Blocking C5 Activation Blood. 128: 158-158. DOI: 10.1182/Blood.V128.22.158.158 |
0.383 |
|
| 2016 |
Carstens EJ, Skarzynski M, Butera V, Lindorfer M, Vire B, Farooqui M, Rader C, Taylor R, Wiestner A. Abstract 1490: Potentiating immunotherapy by targeting complement deposited on cancer cell surfaces Cancer Research. 76: 1490-1490. DOI: 10.1158/1538-7445.Am2016-1490 |
0.368 |
|
| 2015 |
van den Bremer ET, Beurskens FJ, Voorhorst M, Engelberts PJ, de Jong RN, van der Boom BG, Cook EM, Lindorfer MA, Taylor RP, van Berkel PH, Parren PW. Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. Mabs. 7: 672-80. PMID 26037225 DOI: 10.1080/19420862.2015.1046665 |
0.392 |
|
| 2015 |
Taylor RP, Lindorfer MA. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood. 125: 762-6. PMID 25498911 DOI: 10.1182/Blood-2014-10-569244 |
0.427 |
|
| 2015 |
Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ, Golay J. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 100: 77-86. PMID 25344523 DOI: 10.3324/Haematol.2014.107011 |
0.428 |
|
| 2015 |
Skarzynski M, Lindorfer M, Butera V, Vire B, Farooqui M, Rader C, Taylor R, Wiestner A. Monoclonal antibodies targeting cell surface deposited complement fragment C3d potentiate cancer immunotherapy and eliminate antigen loss variants Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P372 |
0.422 |
|
| 2014 |
Ghosh S, Campbell AM, Taylor RP, Edberg JC. Cross-reactivity of anti-dsDNA antibodies. Immunology Today. 8: 75. PMID 25289469 DOI: 10.1016/0167-5699(87)90848-6 |
0.38 |
|
| 2014 |
Taylor RP, Lindorfer MA. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Molecular Pharmacology. 86: 485-91. PMID 24944188 DOI: 10.1124/Mol.114.092684 |
0.422 |
|
| 2014 |
Paixão-Cavalcante D, Torreira E, Lindorfer MA, Rodriguez de Cordoba S, Morgan BP, Taylor RP, Llorca O, Harris CL. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. Journal of Immunology (Baltimore, Md. : 1950). 192: 4844-51. PMID 24729617 DOI: 10.4049/Jimmunol.1303131 |
0.362 |
|
| 2014 |
Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, et al. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. American Journal of Hematology. 89: 757-65. PMID 24723493 DOI: 10.1002/Ajh.23737 |
0.307 |
|
| 2014 |
Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science (New York, N.Y.). 343: 1260-3. PMID 24626930 DOI: 10.1126/Science.1248943 |
0.466 |
|
| 2014 |
Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pettinger AM, Shanafelt TD, Nowakowski GS, Zent CS. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. Journal of Immunology (Baltimore, Md. : 1950). 192: 1620-9. PMID 24431228 DOI: 10.4049/Jimmunol.1302954 |
0.379 |
|
| 2014 |
Sharma R, Zhao H, Al-Saleem FH, Ubaid AS, Puligedda RD, Segan AT, Lindorfer MA, Bermudez R, Elias M, Adekar SP, Simpson LL, Taylor RP, Dessain SK. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor. Molecular Immunology. 57: 247-54. PMID 24184879 DOI: 10.1016/J.Molimm.2013.09.005 |
0.495 |
|
| 2014 |
Taylor RP, Lindorfer MA. The role of complement in mAb-based therapies of cancer. Methods (San Diego, Calif.). 65: 18-27. PMID 23886909 DOI: 10.1016/J.Ymeth.2013.07.027 |
0.379 |
|
| 2013 |
Taylor RP. Gnawing at Metchnikoff's paradigm. Blood. 122: 2922-4. PMID 24159161 DOI: 10.1182/Blood-2013-07-514083 |
0.355 |
|
| 2013 |
Pokrass MJ, Liu MF, Lindorfer MA, Taylor RP. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy. Molecular Immunology. 56: 549-60. PMID 23911412 DOI: 10.1016/J.Molimm.2013.05.242 |
0.449 |
|
| 2013 |
Lindorfer M, Beum P, Taylor R. CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I Antibodies. 2: 598-616. DOI: 10.3390/Antib2040598 |
0.418 |
|
| 2013 |
Beurskens FJ, de Jong RN, Verploegen S, Voorhorst M, Strumane K, Lindorfer MA, Taylor RP, Saphire EO, Burton D, Schuurman J, Parren PW. Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma Blood. 122: 375-375. DOI: 10.1182/Blood.V122.21.375.375 |
0.471 |
|
| 2013 |
Beurskens F, de Jong R, Voorhorst M, Strumane K, Lindorfer M, Taylor R, Ollmann-Saphire E, Burton D, Schuurman J, Parren P. IgG hexamerization mediates efficient C1q docking and complement-dependent cytotoxicity (CDC) Molecular Immunology. 56: 240-241. DOI: 10.1016/J.Molimm.2013.05.012 |
0.375 |
|
| 2012 |
Lindorfer MA, Wiestner A, Zent CS, Taylor RP. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? Oncoimmunology. 1: 959-961. PMID 23162771 DOI: 10.4161/Onci.20368 |
0.389 |
|
| 2012 |
Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath CJ, Fridkis-Hareli M, Selleri C, Lindorfer MA, Taylor RP, Luzzatto L, Holers VM. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 119: 6307-16. PMID 22577173 DOI: 10.1182/Blood-2011-12-398792 |
0.395 |
|
| 2012 |
Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leukemia & Lymphoma. 53: 2218-27. PMID 22475085 DOI: 10.3109/10428194.2012.681657 |
0.396 |
|
| 2012 |
Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. Journal of Immunology (Baltimore, Md. : 1950). 188: 3532-41. PMID 22368276 DOI: 10.4049/Jimmunol.1103693 |
0.424 |
|
| 2012 |
Taylor RP, Lindorfer MA, Beum PV. CD20 mAb-mediated C3b deposition and complement dependent cytotoxicity of tumor cells is enhanced by blocking the action of Factor I Immunobiology. 217: 1148. DOI: 10.1016/J.Imbio.2012.08.055 |
0.329 |
|
| 2011 |
Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. Journal of Immunology (Baltimore, Md. : 1950). 187: 3438-47. PMID 21841127 DOI: 10.4049/Jimmunol.1101189 |
0.38 |
|
| 2011 |
Beum PV, Lindorfer MA, Peek EM, Stukenberg PT, de Weers M, Beurskens FJ, Parren PW, van de Winkel JG, Taylor RP. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers. European Journal of Immunology. 41: 2436-46. PMID 21674476 DOI: 10.1002/Eji.201041204 |
0.392 |
|
| 2011 |
Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pavey ES, Shanafelt TD, Call TG, Kay N, Nowakowski GS, Zent CS. Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab Blood. 118: 2836-2836. DOI: 10.1182/Blood.V118.21.2836.2836 |
0.405 |
|
| 2010 |
Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Seminars in Hematology. 47: 124-32. PMID 20350659 DOI: 10.1053/J.Seminhematol.2010.01.006 |
0.385 |
|
| 2010 |
Daubeuf S, Lindorfer MA, Taylor RP, Joly E, Hudrisier D. The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell Journal of Immunology. 184: 1897-1908. PMID 20089699 DOI: 10.4049/Jimmunol.0901570 |
0.344 |
|
| 2010 |
Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 115: 2283-91. PMID 20068220 DOI: 10.1182/Blood-2009-09-244285 |
0.462 |
|
| 2010 |
Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, Wiestner A. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica. 95: 329-32. PMID 19679883 DOI: 10.3324/Haematol.2009.012484 |
0.335 |
|
| 2010 |
Risitano AM, Pascariello C, Del Vecchio L, Horvath CJ, Fridkis-Hareli M, Holers VM, Lindorfer MA, Taylor RP. C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes Blood. 116: 637-637. DOI: 10.1182/Blood.V116.21.637.637 |
0.394 |
|
| 2010 |
Taylor RP, Zent CS, Beum PV, Lindorfer MA, Weiner G. CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity Blood. 116: 3585-3585. DOI: 10.1182/Blood.V116.21.3585.3585 |
0.382 |
|
| 2010 |
Baig NA, Church AK, Nowakowski GS, Taylor RP, Lindorfer MA, Zent CS. Complement Activation and Cytotoxicity In CLL Cells Treated with Alemtuzumab and Ofatumumab: Evidence for Multiple Mechanisms of Resistance to Complement Dependent Cytotoxicity Blood. 116: 3575-3575. DOI: 10.1182/Blood.V116.21.3575.3575 |
0.432 |
|
| 2010 |
Taylor RP, Beum PV, Lindorfer MA, Peek EM. Examination of the Relative Rates of Rituximab-Mediated Loss of CD20 From B Cells Via Trogocytosis Versus Internalization. Implications for Rituximab Therapy of CLL Blood. 116: 2404-2404. DOI: 10.1182/Blood.V116.21.2404.2404 |
0.402 |
|
| 2010 |
Paixao-Cavalcante D, Lindorfer MA, Morgan BP, Taylor RP, Harris CL. The monoclonal antibody, 3E7, is a multi-functional inhibitor of the alternative pathway that blocks NeF-triggered activation Molecular Immunology. 47: 2292-2292. DOI: 10.1016/J.Molimm.2010.05.276 |
0.393 |
|
| 2010 |
Taylor RP, Beum PV, Lindorfer MA, Pawluzckowycz AW, Beurskens FJ, van de Winkel JG, Parren PW. Complement-dependent lysis of mAb-opsonized B cells can increase resistance of naïve B cells to subsequent attack by mAb and complement Molecular Immunology. 47: 2207-2207. DOI: 10.1016/J.Molimm.2010.05.039 |
0.347 |
|
| 2009 |
Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. Journal of Immunology (Baltimore, Md. : 1950). 183: 749-58. PMID 19535640 DOI: 10.4049/Jimmunol.0900632 |
0.423 |
|
| 2009 |
Taylor RP, Lindorfer MA, Pawluczkowycz AW, Parker CJ. A Novel Approach to Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Both Hemolysis and C3 Deposition Are Blocked by a Monoclonal Antibody (mAb) Specific for the Alternative Pathway of Complement (APC) C3/C5 Convertase. Blood. 114: 157-157. DOI: 10.1182/Blood.V114.22.157.157 |
0.398 |
|
| 2008 |
Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. Journal of Immunology (Baltimore, Md. : 1950). 181: 8120-32. PMID 19018005 DOI: 10.4049/Jimmunol.181.11.8120 |
0.432 |
|
| 2008 |
Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. Journal of Immunology (Baltimore, Md. : 1950). 181: 2916-24. PMID 18684983 DOI: 10.4049/Jimmunol.181.4.2916 |
0.401 |
|
| 2008 |
Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Current Opinion in Immunology. 20: 444-9. PMID 18585457 DOI: 10.1016/J.Coi.2008.05.011 |
0.441 |
|
| 2008 |
Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, Parren PW, van de Winkel JG, Taylor RP. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. Journal of Immunology (Baltimore, Md. : 1950). 181: 822-32. PMID 18566448 DOI: 10.4049/Jimmunol.181.1.822 |
0.381 |
|
| 2008 |
D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocrine, Metabolic & Immune Disorders Drug Targets. 8: 62-8. PMID 18393924 DOI: 10.2174/187153008783928370 |
0.446 |
|
| 2008 |
Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 111: 1456-63. PMID 18024795 DOI: 10.1182/Blood-2007-02-074716 |
0.414 |
|
| 2008 |
Njuguna N, Beum PV, Vire B, Marti GE, White T, Wilson WH, Taylor RP, Wiestner A. High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor Blood. 112: 4208-4208. DOI: 10.1182/Blood.V112.11.4208.4208 |
0.348 |
|
| 2008 |
Taylor RP, Pawluczkowycz AW, Lindorfer MA, van de Winkel JGJ, Beurskens FJ, Parren PWHI. Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX. Blood. 112: 1578-1578. DOI: 10.1182/Blood.V112.11.1578.1578 |
0.426 |
|
| 2008 |
Taylor RP, Beum PV, Stukenberg PT, Pawluczkowycz AW, Lindorfer MA, Beurskens FJ, Parren PWHI, van de Winkel JGJ. Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells. Blood. 112: 1577-1577. DOI: 10.1182/Blood.V112.11.1577.1577 |
0.383 |
|
| 2007 |
Pawluczkowycz AW, Lindorfer MA, Waitumbi JN, Taylor RP. Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria. Journal of Immunology (Baltimore, Md. : 1950). 179: 5543-52. PMID 17911641 DOI: 10.1182/Blood.V110.11.839.839 |
0.411 |
|
| 2007 |
Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. Journal of Immunology (Baltimore, Md. : 1950). 179: 4263-71. PMID 17785867 DOI: 10.4049/Jimmunol.179.6.4263 |
0.396 |
|
| 2007 |
Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology. 44: 3823-37. PMID 17768100 DOI: 10.1016/J.Molimm.2007.06.151 |
0.422 |
|
| 2007 |
Walsh MC, Shaffer LA, Guikema BJ, Body SC, Shernan SK, Fox AA, Collard CD, Fung M, Taylor RP, Stahl GL. Fluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage. Journal of Immunological Methods. 323: 147-59. PMID 17512534 DOI: 10.1016/J.Jim.2007.04.004 |
0.362 |
|
| 2007 |
Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. Nature Clinical Practice. Rheumatology. 3: 86-95. PMID 17299446 DOI: 10.1038/Ncprheum0424 |
0.445 |
|
| 2007 |
Whipple EC, Ditto AH, Shanahan RS, Gatesman JJ, Little SF, Taylor RP, Lindorfer MA. Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys. Molecular Immunology. 44: 377-88. PMID 16631928 DOI: 10.1016/J.Molimm.2006.02.032 |
0.791 |
|
| 2007 |
Taylor RP, Pawluczkowycz AW, Beum PV, Lindorfer MA, Beurskens F, van de Winkel J, Parren P. Complement Activation and Complement-Mediated Killing of B Cells Promoted by Anti-CD20 Monoclonal Antibodies (mAb) Rituximab and Ofatumumab Are Rapid, and Ofatumumab Kills Cells More Rapidly and with Greater Efficacy. Blood. 110: 2352-2352. DOI: 10.1182/Blood.V110.11.2352.2352 |
0.383 |
|
| 2007 |
Taylor RP, Beum PV, Pawluczkowycz AW, Lindorfer MA, Beurskens F, van de Winkel J, Parren P. Spinning Disk Confocal Fluorescent Microscopy (SDCFM) Analyses of Complement Activation Promoted by Anti-CD20 Monoclonal Antibodies (mAbs) Rituximab and Ofatumumab. Blood. 110: 2345-2345. DOI: 10.1182/Blood.V110.11.2345.2345 |
0.443 |
|
| 2007 |
Walsh MC, Shaffer LA, Body SC, Shernan SK, Fox AA, Collard CD, Taylor RP, Stahl GL. A Novel Fluorochrome Linked Immunosorbent Assay (FLISA) for the complete analysis of the mannose binding lectin (MBL) complement pathway. The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A181-D |
0.329 |
|
| 2006 |
Beum PV, Lindorfer MA, Hall BE, George TC, Frost K, Morrissey PJ, Taylor RP. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. Journal of Immunological Methods. 317: 90-9. PMID 17067631 DOI: 10.1016/J.Jim.2006.09.012 |
0.399 |
|
| 2006 |
Zaitsev S, Danielyan K, Murciano JC, Ganguly K, Krasik T, Taylor RP, Pincus S, Jones S, Cines DB, Muzykantov VR. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood. 108: 1895-902. PMID 16735601 DOI: 10.1182/Blood-2005-11-012336 |
0.386 |
|
| 2006 |
Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. Journal of Immunology (Baltimore, Md. : 1950). 176: 2600-9. PMID 16456022 DOI: 10.4049/Jimmunol.176.4.2600 |
0.41 |
|
| 2006 |
DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Molecular Immunology. 43: 1010-9. PMID 15961157 DOI: 10.1016/J.Molimm.2005.05.003 |
0.4 |
|
| 2006 |
Wang S, Racila E, Taylor RP, Weiner GJ. The C3b Component of Complement Inhibits NK Cell Activation Induced by Rituximab-Coated Target Cells. Blood. 108: 2505-2505. DOI: 10.1182/Blood.V108.11.2505.2505 |
0.385 |
|
| 2006 |
Taylor RP, Li Y, Lindorfer MA, Coursar JB, Williams ME. Flow Cytometry and Immunohistochemistry Analyses Reveal That Rituximab/CD20 Complexes Are Removed (Shaved) from Mantle Cell Lymphoma Cells (Z138) Previously Infused Intravenously or Subcutaneously in a SCID Mouse Model, and the Shaving Reaction Can Be Blocked by IVIG. Blood. 108: 2105-2105. DOI: 10.1182/Blood.V108.11.2105.2105 |
0.382 |
|
| 2006 |
Mack DA, Beum PV, Lindorfer MA, Pawluczkowycz AW, Taylor RP. The Shaving Reaction Is Facilitated through Trogocytosis: Concerted Transfer of Both Rituximab (RTX) and the Membrane Dye PKH26 from B Lymphocytes to Macrophages Is Demonstrable by Flow Cytometry, Fluorescence Microscopy, and High Resolution Digital Imaging in a Flow Cytometric Environment. Blood. 108: 2096-2096. DOI: 10.1182/Blood.V108.11.2096.2096 |
0.397 |
|
| 2005 |
Craig ML, Waitumbi JN, Taylor RP. Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: Phagocytosis, transfer, and associations with CR1 Journal of Immunology. 174: 3059-3066. PMID 15728520 DOI: 10.4049/Jimmunol.174.5.3059 |
0.415 |
|
| 2005 |
Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, Graham MA, Geboes K, Rousselle SD, Wagner CL. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. The Journal of Pharmacology and Experimental Therapeutics. 313: 578-85. PMID 15647331 DOI: 10.1124/Jpet.104.079277 |
0.35 |
|
| 2005 |
Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Petroni GR, Eggleton JC, Taylor RP. Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting. Blood. 106: 2970-2970. DOI: 10.1182/Blood.V106.11.2970.2970 |
0.345 |
|
| 2005 |
Taylor RP, Beum PV, Li Y, Lindorfer MA, Williams ME. The Shaving Reaction. Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma Cells (Z138) and Chronic Lymphocytic Leukemia (CLL) Cells by Monocyte/Macrophages: In Vitro Studies and a SCID Mouse Model. Blood. 106: 2968-2968. DOI: 10.1182/Blood.V106.11.2968.2968 |
0.443 |
|
| 2004 |
Beum PV, Kennedy AD, Li Y, Pawluczkowycz AW, Williams ME, Taylor RP. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. Journal of Immunological Methods. 294: 37-42. PMID 15604014 DOI: 10.1016/J.Jim.2004.08.004 |
0.474 |
|
| 2004 |
Gyimesi E, Bankovich AJ, Schuman TA, Goldberg JB, Lindorfer MA, Taylor RP. Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunology Letters. 95: 185-92. PMID 15388259 DOI: 10.1016/J.Imlet.2004.07.007 |
0.402 |
|
| 2004 |
Whipple EC, Shanahan RS, Ditto AH, Taylor RP, Lindorfer MA. Analyses of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice. Journal of Immunology (Baltimore, Md. : 1950). 173: 2297-306. PMID 15294942 DOI: 10.4049/Jimmunol.173.4.2297 |
0.791 |
|
| 2004 |
Beum PV, Kennedy AD, Taylor RP. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. Journal of Immunological Methods. 289: 97-109. PMID 15251416 DOI: 10.1016/J.Jim.2004.03.012 |
0.366 |
|
| 2004 |
Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. Journal of Immunology (Baltimore, Md. : 1950). 172: 3280-8. PMID 14978136 DOI: 10.4049/Jimmunol.172.5.3280 |
0.383 |
|
| 2004 |
Taylor RP, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Densmore JJ, Eggleton J, LoRusso KL, Williams ME. A Pilot Study of Thrice-Weekly Low Dose Rituximab (RTX) in the Treatment of Chronic Lymphocytic Leukemia (CLL) Suggests Enhanced Therapeutic Targeting Compared to Standard Dose Regimens. Blood. 104: 2520-2520. DOI: 10.1182/Blood.V104.11.2520.2520 |
0.333 |
|
| 2004 |
Taylor RP, Whipple EC, Lindorfer MA, Ditto AH, Shanahan RS. A New Vaccine Paradigm To Break Tolerance with Potential Applications for the Immunotherapy of B Cell Lymphoma. Blood. 104: 1411-1411. DOI: 10.1182/Blood.V104.11.1411.1411 |
0.8 |
|
| 2004 |
Taylor RP. CD20 Trek: the next generation Blood. 104: 1592-1592. DOI: 10.1182/Blood-2004-06-2450 |
0.303 |
|
| 2003 |
Lindorfer MA, Jinivizian HB, Foley PL, Kennedy AD, Solga MD, Taylor RP. B cell complement receptor 2 transfer reaction. Journal of Immunology (Baltimore, Md. : 1950). 170: 3671-8. PMID 12646632 DOI: 10.4049/Jimmunol.170.7.3671 |
0.433 |
|
| 2003 |
Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 101: 1071-9. PMID 12393727 DOI: 10.1182/Blood-2002-03-0876 |
0.453 |
|
| 2002 |
Craig ML, Bankovich AJ, Taylor RP. Visualization of the transfer reaction: tracking immune complexes from erythrocyte complement receptor 1 to macrophages. Clinical Immunology (Orlando, Fla.). 105: 36-47. PMID 12483992 DOI: 10.1006/Clim.2002.5266 |
0.382 |
|
| 2002 |
Henderson AL, Lindorfer MA, Kennedy AD, Foley PL, Taylor RP. Concerted clearance of immune complexes bound to the human erythrocyte complement receptor: development of a heterologous mouse model. Journal of Immunological Methods. 270: 183-97. PMID 12379324 DOI: 10.1016/S0022-1759(02)00296-X |
0.431 |
|
| 2001 |
Lindorfer MA, Hahn CS, Foley PL, Taylor RP. Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications. Immunological Reviews. 183: 10-24. PMID 11782244 DOI: 10.1034/J.1600-065X.2001.1830102.X |
0.47 |
|
| 2001 |
Lindorfer MA, Nardin A, Foley PL, Solga MD, Bankovich AJ, Martin EN, Henderson AL, Price CW, Gyimesi E, Wozencraft CP, Goldberg JB, Sutherland WM, Taylor RP. Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. Journal of Immunology (Baltimore, Md. : 1950). 167: 2240-9. PMID 11490011 DOI: 10.4049/Jimmunol.167.4.2240 |
0.436 |
|
| 2001 |
Lindorfer MA, Schuman TA, Craig ML, Martin EN, Taylor RP. A bispecific dsDNAxmonoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus. Journal of Immunological Methods. 248: 125-38. PMID 11223074 DOI: 10.1016/S0022-1759(00)00348-3 |
0.473 |
|
| 2001 |
Hahn CS, French OG, Foley P, Martin EN, Taylor RP. Bispecific monoclonal antibodies mediate binding of dengue virus to erythrocytes in a monkey model of passive viremia. Journal of Immunology (Baltimore, Md. : 1950). 166: 1057-65. PMID 11145685 DOI: 10.4049/Jimmunol.166.2.1057 |
0.353 |
|
| 2001 |
Lindorfer MA, Schuman TA, Craig ML, Martin EN, Taylor RP. A bispecific dsDNA × monoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus Journal of Immunological Methods. 248: 125-138. DOI: 10.1016/S0022-1759(00)00348-3 |
0.376 |
|
| 2000 |
Sokoloff MH, Nardin A, Solga MD, Lindorfer MA, Sutherland WM, Bankovich AJ, Zhau HE, Chung LW, Taylor RP. Targeting of cancer cells with monoclonal antibodies specific for C3b(i). Cancer Immunology, Immunotherapy : Cii. 49: 551-62. PMID 11129326 DOI: 10.1007/S002620000140 |
0.406 |
|
| 2000 |
Craig ML, Bankovich AJ, McElhenny JL, Taylor RP. Clearance of anti-double-stranded DNA antibodies: the natural immune complex clearance mechanism. Arthritis and Rheumatism. 43: 2265-75. PMID 11037886 DOI: 10.1002/1529-0131(200010)43:10<2265::Aid-Anr14>3.0.Co;2-J |
0.429 |
|
| 2000 |
Nardin A, Lindorfer MA, Taylor RP. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells? Molecular Immunology. 36: 827-35. PMID 10698336 DOI: 10.1016/S0161-5890(99)00103-0 |
0.425 |
|
| 2000 |
Reinagel ML, Taylor RP. Transfer of immune complexes from erythrocyte CR1 to mouse macrophages. Journal of Immunology (Baltimore, Md. : 1950). 164: 1977-85. PMID 10657648 DOI: 10.4049/Jimmunol.164.4.1977 |
0.766 |
|
| 1999 |
Craig ML, Reinagel ML, Martin EN, Schlimgen R, Nardin A, Taylor RP. Infusion of bispecific monoclonal antibody complexes into monkeys provides immunologic protection against later challenge with a model pathogen Clinical Immunology. 92: 170-180. PMID 10444361 DOI: 10.1006/Clim.1999.4739 |
0.767 |
|
| 1999 |
Nardin A, Schlimgen R, Holers VM, Taylor RP. A prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model European Journal of Immunology. 29: 1581-1586. PMID 10359112 DOI: 10.1002/(Sici)1521-4141(199905)29:05<1581::Aid-Immu1581>3.0.Co;2-V |
0.442 |
|
| 1998 |
Nardin A, Sutherland WM, Hevey M, Schmaljohn A, Taylor RP. Quantitative studies of heteropolymer-mediated binding of inactivated Marburg virus to the complement receptor on primate erythrocytes. Journal of Immunological Methods. 211: 21-31. PMID 9617828 DOI: 10.1016/S0022-1759(97)00168-3 |
0.45 |
|
| 1998 |
Taylor RP, Nardin A, Sutherland WM. Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor. Cancer Immunology, Immunotherapy : Cii. 45: 152-5. PMID 9435861 DOI: 10.1007/S002620050420 |
0.457 |
|
| 1997 |
Taylor RP, Ferguson PJ, Martin EN, Cooke J, Greene KL, Grinspun K, Guttman M, Kuhn S. Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 mAbs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model. Clinical Immunology and Immunopathology. 82: 49-59. PMID 9000042 DOI: 10.1006/Clin.1996.4286 |
0.411 |
|
| 1997 |
Muzykantov VR, Murciano JC, Taylor RP, Atochina EN, Herraez A. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Analytical Biochemistry. 241: 109-19. PMID 8921172 DOI: 10.1006/Abio.1996.0384 |
0.351 |
|
| 1997 |
Reinagel ML, Gezen M, Ferguson PJ, Kuhn S, Martin EN, Taylor RP. The Primate Erythrocyte Complement Receptor (CR1) as a Privileged Site: Binding of Immunoglobulin G to Erythrocyte CR1 Does Not Target Erythrocytes for Phagocytosis Blood. 89: 1068-1077. DOI: 10.1182/Blood.V89.3.1068 |
0.757 |
|
| 1996 |
Taylor RP, Ferguson PJ. Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation. Journal of Hematotherapy. 4: 357-62. PMID 8581369 DOI: 10.1089/Scd.1.1995.4.357 |
0.468 |
|
| 1995 |
Powers JH, Buster BL, Reist CJ, Martin E, Bridges M, Sutherland WM, Taylor RP, Scheld WM. Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1. Infection and Immunity. 63: 1329-35. PMID 7890390 DOI: 10.1128/Iai.63.4.1329-1335.1995 |
0.485 |
|
| 1995 |
Ferguson PJ, Reist CJ, Martin EN, Johnson C, Greene KL, Kuhn S, Niebur J, Emlen W, Taylor RP. Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. Arthritis and Rheumatism. 38: 190-200. PMID 7848309 DOI: 10.1002/Art.1780380207 |
0.443 |
|
| 1995 |
Muzykantov VR, Taylor RP. Attachment of biotinylated antibody to red blood cells: antigen-binding capacity of immunoerythrocytes and their susceptibility to lysis by complement. Analytical Biochemistry. 223: 142-8. PMID 7695090 DOI: 10.1006/Abio.1994.1559 |
0.403 |
|
| 1994 |
Reist CJ, Liang HY, Denny D, Martin EN, Scheld WM, Taylor RP. Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys. European Journal of Immunology. 24: 2018-25. PMID 8088321 DOI: 10.1002/Eji.1830240913 |
0.478 |
|
| 1993 |
Reist CJ, Wright JD, Labuguen RH, Taylor RP. Human IgG in immune complexes bound to human erythrocyte CR1 is recognized differently than human IgG bound to an erythrocyte surface antigen. Journal of Immunological Methods. 163: 199-208. PMID 8354889 DOI: 10.1016/0022-1759(93)90123-O |
0.439 |
|
| 1993 |
Reist CJ, Combs MJ, Croft BY, Taylor RP. Antigens pre-bound to the primate erythrocyte complement receptor via cross-linked bispecific monoclonal antibody heteropolymers are rapidly cleared from the circulation. European Journal of Immunology. 23: 3021-7. PMID 8223879 DOI: 10.1002/Eji.1830231144 |
0.437 |
|
| 1992 |
Lutz HU, Stammler P, Kock D, Taylor RP. Opsonic potential of C3b-anti-band 3 complexes when generated on senescent and oxidatively stressed red cells or in fluid phase. Advances in Experimental Medicine and Biology. 307: 367-76. PMID 1805599 DOI: 10.1007/978-1-4684-5985-2_33 |
0.38 |
|
| 1992 |
Labuguen RH, Taylor RP, Zimmermann RL. E-rosette formation using heteropolymeric monoclonal antibodies. Immunology Letters. 32: 175-80. PMID 1535335 DOI: 10.1016/0165-2478(92)90111-Z |
0.478 |
|
| 1992 |
Edberg JC, Kimberly RP, Taylor RP. Functional characterization of non-human primate erythrocyte immune adherence receptors: Implications for the uptake of immune complexes by the cells of the mononuclear phagocytic system European Journal of Immunology. 22: 1333-1339. PMID 1376254 DOI: 10.1002/Eji.1830220602 |
0.453 |
|
| 1991 |
Taylor RP, Pocanic F, Reist C, Wright EL. Complement-opsonized IgG antibody/dsDNA immune complexes bind to CR1 clusters on isolated human erythrocytes. Clinical Immunology and Immunopathology. 61: 143-60. PMID 1833104 DOI: 10.1016/S0090-1229(05)80020-0 |
0.399 |
|
| 1991 |
Taylor RP, Sutherland WM, Reist CJ, Webb DJ, Wright EL, Labuguen RH. Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment. Proceedings of the National Academy of Sciences of the United States of America. 88: 3305-9. PMID 1826564 DOI: 10.1073/Pnas.88.8.3305 |
0.455 |
|
| 1989 |
Edberg JC, Tosic L, Taylor RP. Immune adherence and the processing of soluble complement-fixing antibody/DNA immune complexes in mice. Clinical Immunology and Immunopathology. 51: 118-32. PMID 2924435 DOI: 10.1016/0090-1229(89)90212-2 |
0.395 |
|
| 1989 |
Tosic L, Sutherland WM, Kurek J, Edberg JC, Taylor RP. Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose. Journal of Immunological Methods. 120: 241-9. PMID 2786912 DOI: 10.1016/0022-1759(89)90248-2 |
0.433 |
|
| 1989 |
Schifferli JA, Taylor RP. Physiological and pathological aspects of circulating immune complexes. Kidney International. 35: 993-1003. PMID 2651776 DOI: 10.1038/Ki.1989.83 |
0.391 |
|
| 1989 |
Kimberly RP, Edberg JC, Merriam LT, Clarkson SB, Unkeless JC, Taylor RP. In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees Journal of Clinical Investigation. 84: 962-970. PMID 2527255 DOI: 10.1172/Jci114259 |
0.363 |
|
| 1987 |
Emlen W, Pisetsky DS, Taylor RP. Antibodies to DNA. A perspective. Arthritis and Rheumatism. 29: 1417-26. PMID 3541943 DOI: 10.1002/Art.1780291201 |
0.339 |
|
| 1987 |
Taylor RP, Edberg JC, Kujala GA, Sloman AJ, Wilson CC, Cronin ME. The interaction of antibody/DNA immune complexes with complement. Influence of antibody class and DNA conformation. Arthritis and Rheumatism. 30: 176-85. PMID 3493781 DOI: 10.1002/Art.1780300208 |
0.412 |
|
| 1987 |
Cosio FG, Hebert LA, Birmingham DJ, Dorval BL, Bakaletz AP, Kujala GA, Edberg JC, Taylor RP. Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate Clinical Immunology and Immunopathology. 42: 1-9. PMID 3491711 DOI: 10.1016/0090-1229(87)90167-X |
0.34 |
|
| 1985 |
Horgan C, Taylor RP. Complement-component-C3-opsonized immunoglobulin G anti-DNA antibodies do not bind effectively to red blood cells unless aggregated on a high-Mr DNA matrix. The Biochemical Journal. 224: 755-9. PMID 6525175 DOI: 10.1042/bj2240755 |
0.336 |
|
| 1985 |
Taylor RP, Horgan C. Quantitative determination of anti-dsDNA antibodies and antibody/dsDNA stoichiometries in prepared, soluble complement-fixing antibody/dsDNA immune complexes. Molecular Immunology. 21: 853-62. PMID 6334233 DOI: 10.1016/0161-5890(84)90139-1 |
0.481 |
|
| 1985 |
Taylor RP, Horgan C, Hooper M, Burge J. Dynamics of interaction between complement-fixing antibody/dsDNA immune complexes and erythrocytes. In vitro studies and potential general applications to clinical immune complex testing. The Journal of Clinical Investigation. 75: 102-11. PMID 3917462 DOI: 10.1172/Jci111660 |
0.418 |
|
| 1984 |
Horgan C, Taylor RP. Studies on the kinetics of binding of complement-fixing dsDNA/anti-dsDNA immune complexes to the red blood cells of normal individuals and patients with systemic lupus erythematosus. Arthritis and Rheumatism. 27: 320-9. PMID 6546694 DOI: 10.1002/Art.1780270312 |
0.434 |
|
| 1984 |
Taylor RP, Horgan C, Harbin A, Burge J. Suramin inhibits the binding of complement-fixing antibody/double-stranded DNA immune complexes to CR1. Clinical Immunology and Immunopathology. 33: 220-31. PMID 6488590 DOI: 10.1016/0090-1229(84)90077-1 |
0.452 |
|
| 1983 |
Taylor RP, Horgan C, Buschbacher R, Brunner CM, Hess CE, O'Brien WM, Wanebo HJ. Decreased complement mediated binding of antibody/3H-dsDNA immune complexes to the red blood cells of patients with systemic lupus erythematosus, rheumatoid arthritis, and hematologic malignancies. Arthritis and Rheumatism. 26: 736-44. PMID 6860375 DOI: 10.1002/Art.1780260606 |
0.423 |
|
| 1982 |
Waller SJ, Taylor RP, Johnson ML. Analysis of the complement-fixing potential of dsDNA/anti-dsDNA immune complexes Rheumatology International. 1: 187-193. DOI: 10.1007/Bf00541175 |
0.452 |
|
| 1981 |
Waller SJ, Taylor RP, Wright EL, Morley KW, Johns M. DNA/anti-DNA complexes: correlation of size and complement fixation. Arthritis and Rheumatism. 24: 651-7. PMID 7236322 DOI: 10.1002/Art.1780240504 |
0.442 |
|
| 1981 |
Birchmore DA, Taylor RP, Waller SJ, Davis JS, Morley KW. Interaction between rheumatoid factor and antibody/DNA complexes: enhancement of complement fixation. Arthritis and Rheumatism. 24: 527-33. PMID 7213431 DOI: 10.1002/Art.1780240313 |
0.426 |
|
| 1981 |
Taylor RP, Andrews BS, Morley KW, Conlon T. Quantitative studies of the interaction of 3H-dsDNA/anti-DNA immune complexes with complement: comparison and evaluation of the Raji cell, the solution phase C1Q, and the red blood cell linked complement fixation radioimmunoassays. Rheumatology International. 1: 29-34. PMID 6981180 DOI: 10.1007/Bf00541220 |
0.426 |
|
| 1981 |
Taylor RP, Waller SJ, Davis JS, Winfield JB, Morley KW, Wright EL. Studies of artificial cryoprecipitates containing anti-DNA antibody activity. Rheumatology International. 1: 1-6. PMID 6981179 DOI: 10.1007/Bf00541215 |
0.315 |
|
| 1981 |
Barada FA, Andrews BS, Davis JS, Taylor RP. Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis and Rheumatism. 24: 1236-44. PMID 6975630 DOI: 10.1002/Art.1780241003 |
0.385 |
|
| 1980 |
Pedersen SE, Taylor RP, Morley KW, Wright EL. Stability of DNA/ANTI-DNA complexes. IV. Complement fixation. Journal of Immunological Methods. 38: 269-80. PMID 7440976 DOI: 10.1016/0022-1759(80)90275-6 |
0.474 |
|
| 1979 |
Waller SJ, Taylor RP, Andrews BS. A polyethylene glycol radioimmunoprecipitation assay for human immunoglobulin G. Journal of Immunological Methods. 30: 171-7. PMID 501100 DOI: 10.1016/0022-1759(79)90091-7 |
0.391 |
|
| 1979 |
Riley RL, McGrath H, Taylor RP. Detection of low avidity anti-DNA antibodies in systemic lupus erythematosus Arthritis and Rheumatism. 22: 219-225. PMID 311203 DOI: 10.1002/Art.1780220303 |
0.644 |
|
| 1977 |
Taylor RP, Riley RL, Weber DJ. Spectroscopic and kinetic studies of the active site of anti-trinitrophenyl antibodies Immunochemistry. 14: 227-229. PMID 863469 DOI: 10.1016/0019-2791(77)90199-9 |
0.677 |
|
| 1977 |
Riley RL, Taylor RP, Shaffner DH. SDS induced conformational changes in the combining site of anti-trinitrophenyl antibodies. A kinetic study Immunochemistry. 14: 221-225. PMID 863468 DOI: 10.1016/0019-2791(77)90198-7 |
0.654 |
|
| 1977 |
Taylor RP, Riley RL, Weber D. Energy transfer: A general method for the study of protein-nucleic acid interactions Archives of Biochemistry and Biophysics. 180: 208-213. PMID 856043 DOI: 10.1016/0003-9861(77)90027-3 |
0.572 |
|
| 1976 |
Taylor RP, Gettman D. A chemical probe of the active site of anti-trinitrophenyl antibodies. Immunochemistry. 13: 299-306. PMID 939574 DOI: 10.1016/0019-2791(76)90338-4 |
0.384 |
|
| Show low-probability matches. |